The survival time of chronic leukemia cannot be generalized and is determined by the specific disease classification and progression of the disease.
Chronic leukemia is a kind of malignant tumor of bone marrow hematopoietic system, but the tumor cells have a certain ability to differentiate and mature, and the bone marrow and peripheral blood are dominated by relatively mature tumor cells. Clinically, it is divided into two types, chronic granulocytic leukemia and chronic lymphatic leukemia.
1. Survival time of chronic granulocytic leukemia, with the widespread use of tyrosine kinase inhibitor-targeted drugs (imatinib), the survival time of patients with chronic granulocytic leukemia has been greatly prolonged, and many patients have even reached cytogenetic deep remission, which allows them to live disease-free all the time and is expected to discontinue the drug in the future.
2. Chronic lymphocytic leukemia is the most typical chronic lymphocytic leukemia, and there are also juvenile lymphocytic leukemia, hairy cell leukemia, and large granular lymphocytic leukemia.
Taking chronic lymphocytic leukemia as an example, its prognosis is related to the patient’s age of onset, stage, lymphocyte count, gene mutation, etc. The median survival period is 35-63 months, which is related to the stage, and there are also patients who can survive up to 10 years or more. Drugs include nitrogen mustard phenylbutyrate, ibrutinib and so on.
In conclusion, chronic leukemia is a slow clinical development of the disease, with the continuous emergence of new drugs and new therapeutic means, the patient’s survival is expected to be greatly improved, it is recommended to go to the hospital to find a doctor to clarify the status of the disease, and constantly improve the survival benefit, the treatment under the guidance of the physician.